International Journal of Cancer · 2018 · 12 citations · 37 references
MedicineCancer BiologyOncologyEpigeneticsEpigenomicsMolecular OncologyCancer BiomarkersCancer EpigeneticsEpigenetic Biomarker DiscoveryEpigenetic BiomarkersEpigenetic Regulation In CancerOvarian CancerCancer Epigenetic BiomarkersCancer Genomic Biomarker DiscoveryEpigenetic Biomarker ValidationEpigenetic Signature DiscoveryOncogenic TransformationOvarian Cancer Prognostic BiomarkersPrognostic BiomarkersTissue Microarrays
Precision medicine requires markers for therapeutic guidance. The purpose of this study was to determine whether epithelial ovarian cancer (EOC) epigenetics can lead to the identification of biomarkers for precision medicine. Through integrative methylomics, we discovered and validated the epigenetic signature of NEFH and HS3ST2 as an independent prognostic factor for type II EOC in our dataset (n = 84), and two independent methylomics datasets (total n = 467). Integrated transcriptomics dataset (n = 1147) and tissue microarrays (n = 54) of HS3ST2 also related to high-methylation statuses and the EOC prognosis. Mechanistic explorations of HS3ST2 have assessed responses to oncogenic stimulations such as IL-6, EGF, and FGF2 in cancer cells. The combination of HS3ST2 and various oncogenic ligands also confers the worse outcome. 3-O-sulfation of heparan sulfate by HS3ST2 makes ovarian cancer cells intrinsically sensitive to oncogenic signals, which sheds new light on the application of HS3ST2 as a companion diagnostic for targeted therapy using kinase inhibitors or therapeutic antibodies.
37
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +15